Agenus Inc. [AGEN] gain 5.97% so far this year. What now?


Agenus Inc. [NASDAQ: AGEN] loss -2.88% or -0.1 points to close at $3.37 with a heavy trading volume of 2888097 shares. The company report on December 22, 2021 that Balstilimab Plus Zalifrelimab Data Published in Journal of Clinical Oncology (JCO).

Objective response rate (ORR) of 32.8% in PD-L1-positive patients and 25.6% in all patients regardless of PD-L1 status.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Both ORRs and durability of responses are higher than what has been demonstrated with approved therapies for these patients.

It opened the trading session at $3.46, the shares rose to $3.62 and dropped to $3.37, the range by which the price of stock traded the whole day. The daily chart for AGEN points out that the company has recorded -38.05% loss over the past six months. However, it is still -34.8% lower than its most recent low trading price.

If we look at the average trading volume of 4.47M shares, AGEN reached to a volume of 2888097 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Agenus Inc. [AGEN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AGEN shares is $10.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AGEN stock is a recommendation set at 1.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Agenus Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 16, 2021. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on November 19, 2019, representing the official price target for Agenus Inc. stock. On October 28, 2016, analysts decreased their price target for AGEN shares from 10 to 5.

The Average True Range (ATR) for Agenus Inc. is set at 0.21, with the Price to Sales ratio for AGEN stock in the period of the last 12 months amounting to 2.77. The Price to Book ratio for the last quarter was 18.72, with the Price to Cash per share for the same quarter was set at 1.04.

Trading performance analysis for AGEN stock

Agenus Inc. [AGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.53. With this latest performance, AGEN shares gained by 4.33% in over the last four-week period, additionally sinking by -38.05% over the last 6 months – not to mention a rise of 3.37% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGEN stock in for the last two-week period is set at 45.19, with the RSI for the last a single of trading hit 47.12, and the three-weeks RSI is set at 42.78 for Agenus Inc. [AGEN]. The present Moving Average for the last 50 days of trading for this stock 3.72, while it was recorded at 3.49 for the last single week of trading, and 4.46 for the last 200 days.

Agenus Inc. [AGEN]: A deeper dive into fundamental analysis

Agenus Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.10.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at Agenus Inc. [AGEN]

There are presently around $417 million, or 47.90% of AGEN stock, in the hands of institutional investors. The top three institutional holders of AGEN stocks are: BLACKROCK INC. with ownership of 16,582,716, which is approximately 2.71% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 14,935,458 shares of the stock with an approximate value of $51.83 million in AGEN stocks shares; and STATE STREET CORP, currently with $42.73 million in AGEN stock with ownership of nearly 11.765% of the company’s market capitalization.

107 institutional holders increased their position in Agenus Inc. [NASDAQ:AGEN] by around 18,908,749 shares. Additionally, 50 investors decreased positions by around 14,424,175 shares, while 30 investors held positions by with 86,813,364 shares. The mentioned changes placed institutional holdings at 120,146,288 shares, according to the latest SEC report filing. AGEN stock had 41 new institutional investments in for a total of 2,851,046 shares, while 18 institutional investors sold positions of 9,461,831 shares during the same period.